Yu-Hsin Lin - 31 Mar 2026 Form 4 Insider Report for BELITE BIO, INC (BLTE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: BLTE
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2026, 16:15:07 UTC
Prior SEC filing: 18 Mar 2026
Next SEC filing: 13 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Yu-Hsin Lin

Key filing fact

Yu-Hsin Lin filed Form 4 for BELITE BIO, INC (BLTE) on 02 Apr 2026.

Key facts

This page summarizes Yu-Hsin Lin's Form 4 filing for BELITE BIO, INC (BLTE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Apr 2026, 16:15.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001965964 Primary reporting owner

Lin Yu-Hsin

Relationship: Chief Executive Officer, Director
Address: 12750 HIGH BLUFF DRIVE, SUITE 475, SAN DIEGO
Signature: /s/ Yu-Hsin Lin
Signature date: 02 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLTE transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +206,954
Change %: +100%
Price: $0.000000^*
Shares after: 413,908
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 206,954
Exercise price: $0.4386
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On December 23, 2020, the reporting person was granted an option which shall vest in installments upon satisfaction of certain performance criteria. 206,954 ordinary shares subject to the option that had previously vested remain exercisable. One of the performance criteria was met on 3/31/2026, resulting in vesting of the option as to additional 206,954 ordinary shares.